^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DS-7423

    i
    Other names: DS-7423
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    mTOR inhibitor, PI3K inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. (PubMed, Mol Cancer Ther)
    Concomitant targeting of PI3K/mTOR with either HER2 or mGluR1 inhibitors results in decreased cell survival and tumor growth in xenograft studies. Our results suggest a novel therapeutic possibility for PTEN wild-type-PI3K/AKT mutant prostate cancer patients based in the combination of PI3K/mTOR blockade with HER2 or mGluR1 inhibitors.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 mutation
    |
    DS-7423